Skip to main content
. 2024 Aug 30;15:1399983. doi: 10.3389/fneur.2024.1399983

Figure 4.

Figure 4

MRI Rad-score of each patient and model validation. (A) MRI Rad-score of each patient receiving second-line osimertinib therapy. (B) Kaplan–Meier curve exhibiting the iPFS of patients with MRI Rad-score > and ≤ 199. iPFS, intracranial progression-free survival.